By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

OK

By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.

Novo Nordisk

Four oral GLP-1R products in Phase III trials as race intensifies Clinical Trials Arena09:30GLP-1R Obesity Pharma

Pharma giants vie for oral GLP-1R approval PharmaTimes13:21GLP-1R Obesity Pharma

Novo Nordisk, Eli Lilly shares rise as Biden expanse coverage to anti-obesity drugs Proactive Investors (US)18:06Ozempic Joe Biden Pharma

Novo Nordisk India execs urge early Wegovy launch as rival Eli Lilly looms The Business Standard06:26Ozempic Joe Biden Pharma

Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks Pharmaceutical Technology12:16Heart Disease Ozempic Canada

Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack CBC.ca21:29Heart Disease Ozempic Canada

Novo Nordisk announces £18.5 million of funding for a further 20 Postdoctoral Fellows University of Oxford15:50Obesity Universities Pharma

Renewal of the Novo Nordisk – University of Oxford Fellowship Programme University of Oxford13:55Obesity Universities Pharma

Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why Proactive Investors (US)11:41AstraZeneca Pharma JPMorgan Chase

ETFs tracking securitized debt, AI and Novo Nordisk add to industry’s banner 2024 Yahoo! UK & Ireland23:35Ozempic AI Business Closures

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ as ‘fundamentally different’ for Denmark’s… Fortune11:14Ozempic Pharma World Economic News

Novo Nordisk Foundation targets US, Europe after obesity boost BNN Bloomberg16:18Ozempic Pharma World Economic News

A 92% discount for Ozempic in Germany is good news for medical tourism eTurboNews01:52Ozempic Germany Pharma

Novo Nordisk is scaling back its hiring spree in Denmark BNN Bloomberg17:34Ozempic Denmark Pharma

Weight loss drug wars heat up: Amgen challenges Eli Lilly, Novo's dominance Benzinga14:26Amgen Eli Lilly Obesity

Amgen falls as weight-loss shot results disappoint street Yahoo! US16:58Amgen Eli Lilly Obesity

Latest News

In the last half-hour

Are weight loss drugs Ozempic and Wegovy overplayed as a magic pill? Indian Express04:58

In the last 6 hours

ETFs tracking securitized debt, AI and Novo Nordisk add to industry’s banner 2024 Yahoo! UK & Ireland23:35 3-Dec-24

Yesterday

GLP-1 Drugs: Brand Companies Push FDA to Limit Compounding JD Supra15:35 3-Dec-24

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance Benzinga14:26 3-Dec-24

Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum Benzinga14:26 3-Dec-24

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of… GlobeNewswire (Press Release)13:05 3-Dec-24

Novo Nordisk and AstraZeneca top 2025 drug picks for US investment bank - read why Proactive Investors (US)13:02 3-Dec-24

Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why Proactive Investors (US)11:41 3-Dec-24

Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk GlobeNewswire (Press Release)11:01 3-Dec-24

Four oral GLP-1R products in Phase III trials as race intensifies Clinical Trials Arena09:30 3-Dec-24

The weight is over: How GLP-1 treatments are reshaping pharma and beyond Allianz Trade09:05 3-Dec-24

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms The Times of India06:26 3-Dec-24

Novo Nordisk India execs urge early Wegovy launch as rival Eli Lilly looms The Business Standard06:26 3-Dec-24

In the last 7 days

Novo Nordisk Denied Increased California Research Tax Credits Bloomberg Law23:21 2-Dec-24

Top pharmaceutical companies have increasing budgets for research and development Bursa.ro22:01 2-Dec-24

Potential conflicts of interest may haunt Dr. Oz’s confirmation to run Medicare, Medicaid Boston Globe19:57 2-Dec-24

Novo Nordisk announces £18.5 million of funding for a further 20 Postdoctoral Fellows University of Oxford15:50 2-Dec-24

Novo Nordisk Announces Major Share Buyback Program TipRanks14:24 2-Dec-24

Renewal of the Novo Nordisk – University of Oxford Fellowship Programme University of Oxford13:55 2-Dec-24

Pharma giants vie for oral GLP-1R approval PharmaTimes13:21 2-Dec-24

Conflicts of Interest Complicate Dr. Oz’s Nomination Political Wire12:59 2-Dec-24

Novo Nordisk A/S - share repurchase programme GlobeNewswire (Press Release)11:49 2-Dec-24

4 oral GLP-1R obesity drugs in race for approval, Novo Nordisk leads: report DD News11:00 2-Dec-24

A 92% Discount for Ozempic in Germany is Good News for Medical Tourism eTurboNews01:52 2-Dec-24

Weight Loss Drugs Continue to Power Denmark's Economy Apricitas Economics15:34 1-Dec-24

Brazil’s rising obesity rates fuel major demand for weight-loss drugs The Brazilian Report12:07 1-Dec-24

What the Options Market Tells Us About Novo Nordisk Nasdaq17:01 29-Nov-24

Is Novo Nordisk Stock a Buy? The Motley Fool10:43 29-Nov-24

Korea to restrict telemedicine prescriptions for Wegovy starting Dec. 2 Korea Biomedical Review07:47 29-Nov-24

Diabetes Killed 55,000 Nigerians In 2024 – Prof Fasanmade Leadership, Nigeria04:41 29-Nov-24

Wegovy hits the People’s Republic, at last The Economist13:58 28-Nov-24

Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks Pharmaceutical Technology12:16 28-Nov-24

Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack CBC.ca21:29 27-Nov-24

Canada approves new obesity drug to reduce risk of non-fatal heart attack CTV News Edmonton19:57 27-Nov-24

Weight-loss drug now approved in Canada to reduce risk of non-fatal heart attacks Toronto Sun19:28 27-Nov-24

The race for approval: oral GLP-1R therapies in obesity Pharmaceutical Technology18:28 27-Nov-24

Novo Nordisk appoints new general manager in Bulgaria SeeNews15:37 27-Nov-24

Canada Diabetes Devices Market Forecast Report and Company Analysis 2024-2032, Featuring Novo Nordisk, Eli Lilly,… GlobeNewswire (Press Release)15:22 27-Nov-24

Commission approves acquisition of Sylvan by Novo Nordisk Foundation and KKR Thomson Reuters - Practical Law14:38 27-Nov-24

LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs Zacks14:03 27-Nov-24

Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack CTV News Calgary12:45 27-Nov-24

In 2024, the US and Europe led in pharma value creation while GLP-1s disrupted the landscape Drug Discovery & Development07:40 27-Nov-24

Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals Seeking Alpha03:34 27-Nov-24

In the last month

Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs Investopedia18:27 26-Nov-24

Biden admin looks to add weight loss drug coverage to Medicaid Yahoo! UK & Ireland18:09 26-Nov-24

Novo Nordisk, Eli Lilly shares rise as Biden expanse coverage to anti-obesity drugs Proactive Investors (US)18:06 26-Nov-24

Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark BNN Bloomberg17:34 26-Nov-24

Amgen Falls as Weight-Loss Shot Results Disappoint Street Yahoo! US16:58 26-Nov-24

Novo Nordisk Stock Jumps on Biden Weight Loss Proposal Despite Upcoming Trump Presidency TipRanks16:07 26-Nov-24

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs Benzinga15:11 26-Nov-24

1 top growth stock on my Christmas buy list Motley Fool (UK)13:23 26-Nov-24

Novo Nordisk shares rise as Biden proposes obesity care coverage Yahoo! UK & Ireland12:23 26-Nov-24

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ as ‘fundamentally different’ for Denmark’s… Fortune11:14 26-Nov-24

Allurion launches compounded GLP-1 program as FDA aims to end access Yahoo! US20:03 25-Nov-24

Allurion launches compounded GLP-1 program as FDA aims to ends access Yahoo! US19:53 25-Nov-24

Novo Nordisk Launches Major Share Repurchase Program TipRanks16:53 25-Nov-24

[Latest] Global Injectable Drug Delivery Devices Market Size/Share Worth USD 40,956.3 Million by 2033 at a 10.21% CAGR: … GlobeNewswire (Press Release)16:35 25-Nov-24

Novo Nordisk Foundation Targets US, Europe After Obesity Boost BNN Bloomberg16:18 25-Nov-24

Australia Diabetes Market Forecasts and Company Analysis 2024-2032, Novo Nordisk, Eli Lilly, Roche, Abbott… GlobeNewswire (Press Release)15:17 25-Nov-24

Exclusive-Thousands turn to Wegovy copies each month as FDA considers shortage status Yahoo! UK & Ireland11:17 25-Nov-24

Danish investor snaps up Benchmark genetics business in £260 million deal Intrafish10:37 25-Nov-24

Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly,… FiercePharma08:09 25-Nov-24

Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial? Seeking Alpha07:57 25-Nov-24

Wait, Why Is Novo Selling Weight Loss Drugs for So Cheap in China? Futurism12:52 24-Nov-24

Ozempic has been a medical breakthrough - but the online risks remain i News17:06 22-Nov-24

“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl Verdict Medical Devices16:26 22-Nov-24

Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock Zacks15:39 22-Nov-24

Squid Game: Direct Drug Delivery Into GI Tract Using Cephalopod-Inspired Capsules Genetic Engineering and Biotechnology News12:57 22-Nov-24

Interesting NVO Put And Call Options For January 2025 Nasdaq16:49 21-Nov-24

Wegovy on sale in China, cheaper than US Salon.com16:42 21-Nov-24

Ingestible Capsule Pump Drugs Directly into Walls of GI Tract Hospimedica16:11 21-Nov-24

Ingestible capsule releases a burst of drugs directly into the walls of the GI tract Inspired By The Jets... News-Medical.Net14:03 21-Nov-24

Analysis-Wall Street awaits Amgen weight-loss drug data expected to move shares Yahoo! US11:27 21-Nov-24

Squid-inspired technology could replace needles for medications and vaccines News-Medical.Net16:10 20-Nov-24

A bioinspired capsule can pump drugs directly into the walls of the GI tract Massachusetts Institute of Technology16:06 20-Nov-24

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Pharmaceutical… PR Newswire (Press Release)15:34 20-Nov-24

Is Novo Nordisk Stock a Buy Right Now? The Motley Fool11:15 20-Nov-24

Drugmakers and pharmacists battle over who gets to make obesity drugs NPR11:05 20-Nov-24

Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH Scrip Pharma Intelligence22:40 19-Nov-24

Semaglutide 2.4 mg Reduces All-Cause Hospital Admissions HumanProgress22:20 19-Nov-24

McGuireWoods Lands Health Ace, Former GC From Akin In NY Law36021:27 19-Nov-24

ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements … PR Newswire (Press Release)19:49 19-Nov-24

Novo Nordisk Pushes for FDA Listing of Semaglutide Products JD Supra18:47 19-Nov-24

Novo Nordisk sells hit weight-loss drug in China—at fraction of US price Ars Technica17:14 19-Nov-24

Stock Watch: Dashing Great GLP-1 Agonist Expectations Scrip Pharma Intelligence16:42 19-Nov-24

Novo Erases 2024 Gain, Wiping Out $210 Billion in Value BNN Bloomberg13:25 19-Nov-24

Novo Nordisk's obesity drug Wegovy goes on sale in China MailOnline09:40 19-Nov-24

Novo Nordisk hosts World Diabetes Day 2024 symposium Korea Biomedical Review05:04 19-Nov-24

Popular weight-loss drug Wegovy goes on sale in China BBC04:40 19-Nov-24

MSF slams Novo Nordisk for SA’s insulin pen shortage Business Day03:59 19-Nov-24

Novo Nordisk launches Wegovy weight drug in China at fraction of US price Proactive Investors (Canada)19:05 18-Nov-24

Novo Nordisk’s Ambitious Share Buyback Initiative TipRanks16:51 18-Nov-24

Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost Benzinga16:20 18-Nov-24

Novo Nordisk launches Wegovy weight drug in China at fraction of price Proactive Investors (US)15:34 18-Nov-24

Novo Nordisk Launches Wegovy in China With Prices Well Below US BNN Bloomberg12:51 18-Nov-24

3 Growth Stocks You Can Buy Right Now Without Any Hesitation The Motley Fool11:04 18-Nov-24

A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug Quartz10:02 18-Nov-24

South Africa: MSF Slams Novo Nordisk for South Africa's Insulin Pen Shortage AllAfrica04:38 18-Nov-24

Novo Nordisk Insulin Plans Spark Angst Among Diabetes Patients BNN Bloomberg10:44 16-Nov-24

Novo-Nordisk Becomes Oversold (NVO) Nasdaq18:11 15-Nov-24

Terry Smith talks performance, AI and the UK market Investors Chronicle15:31 15-Nov-24

MSF slams Novo Nordisk for South Africa’s insulin pen shortage Ground Up14:39 15-Nov-24

Omega halts sole clinical-stage program to prioritize Novo Nordisk collab and liver, obesity… FierceBiotech11:13 15-Nov-24

Women in STEM with Avideh Nazeri Drug Target Review10:02 15-Nov-24

Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead? The Motley Fool09:07 15-Nov-24

Ascendis Pharma Reports Third Quarter 2024 Financial Results GlobeNewswire (Press Release)21:09 14-Nov-24

Citing 'capacity constraints,' Novo Nordisk plots global wind-down of human insulin pen… FiercePharma19:36 14-Nov-24

Novo Nordisk to phase out its production of human insulin pens globally ENDPOINTS16:12 14-Nov-24

Protesters demand that Novo Nordisk reduces price of analogue insulin pens Eyewitness News13:56 14-Nov-24

Is AstraZeneca a Buy as It Eyes the Weight Loss Market? The Motley Fool12:16 14-Nov-24

Novo Nordisk Executives Purchase ADRs on NYSE TipRanks11:40 14-Nov-24

Pharma packaging group West announces 330 jobs for Dublin The Irish Times05:06 14-Nov-24

Ozempic MDL Plaintiffs Say Eli Lilly, Novo Nordisk Hid Risks Law36003:07 14-Nov-24

Novo Nordisk seeks FDA action to block compounded Ozempic copies, citing safety concerns Proactive Investors (Australia)01:31 14-Nov-24

See Which Of The Latest 13F Filers Holds Novo-Nordisk Nasdaq19:54 13-Nov-24

view more headlines

4 Dec 04:58

About our Novo Nordisk news

Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our NewsNow feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.